Comparison of Clinical Features and Treatment Outcome in Benign and Malignant Lacrimal Sac Tumors

Purpose. To compare the clinical characteristics and treatment outcome between benign and malignant lacrimal sac tumors. Methods. We retrospectively reviewed the medical records of all patients with pathologically confirmed lacrimal sac lesions from 1995 to 2018 in a tertiary medical center. Results...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2020, Vol.2020 (2020), p.1-4
Main Authors: Hsu, Wen-Ming, Kao, Shu-Ching, Tsai, Chieh-Chih, Kuo, Che-Yuan, Liu, Catherine Jui-Ling
Format: Article
Language:English
Subjects:
Age
Benign
Cancer
Clinical outcomes
Diagnosis
Eye Neoplasms - pathology
Eye Neoplasms - therapy
Female
Gender
Health care facilities
Humans
Injuries
Lacrimal Apparatus - pathology
Lacrimal gland and Nasolacrimal duct
Lesions
Male
Malignancy
Medical records
Metastases
Metastasis
Middle Aged
Mortality
Nose
Paranasal sinuses
Patient outcomes
Patients
Radiation therapy
Sinus
Sinuses
Tinnitus
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose. To compare the clinical characteristics and treatment outcome between benign and malignant lacrimal sac tumors. Methods. We retrospectively reviewed the medical records of all patients with pathologically confirmed lacrimal sac lesions from 1995 to 2018 in a tertiary medical center. Results. Among 65 eligible cases, 46 (70.8%) were benign lacrimal sac tumors and 19 (29.2%) were malignant lacrimal sac tumors. Secondary malignancy from nasal or paranasal cancer accounted for 47% of malignant lacrimal sac tumors. The patient’s mean age at the time of diagnosis was 60 years in the benign group and 48 years in the malignant group (p=0.03). The most common presenting symptoms were a palpable lump/mass and epiphora in both groups. Palpable mass extending above the medial canthal tendon was noted in 9% of the benign group and in 74% of the malignant group, respectively (p
ISSN:2314-6133
2314-6141
DOI:10.1155/2020/3545839